{"id":245862,"date":"2012-02-21T23:10:03","date_gmt":"2012-02-21T23:10:03","guid":{"rendered":"http:\/\/www.eugenesis.com\/sonic-healthcare-grabs-market-share\/"},"modified":"2012-02-21T23:10:03","modified_gmt":"2012-02-21T23:10:03","slug":"sonic-healthcare-grabs-market-share","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/pathology\/sonic-healthcare-grabs-market-share.php","title":{"rendered":"Sonic Healthcare grabs market share"},"content":{"rendered":"<p><p>                   SONIC Healthcare lifted first half profit by eight per cent      to $146 million as it continues to take a greater share of      the market despite global uncertainty.           <\/p>\n<p>    &nbsp;The pathology and radiology provider said its net profit    after tax was $146 million in the six months to December 31,    2011, up eight per cent from $143 million in the prior    corresponding period.  <\/p>\n<p>    Revenue was $1.69 billion, up 12 per cent from $1.64 billion    over the same period last year.  <\/p>\n<p>    Earnings before interest, taxes, depreciation, and amortisation    (EBITDA) during the six months were $304 million, up 14 per    cent from $297 million.  <\/p>\n<p>    The company declared a 24 per cent dividend per share which was    unchanged from the prior year. The dividend was 35 per cent    franked.  <\/p>\n<p>    The company also said it was on track to achieve its full-year    guidance of 10 to 15 per cent earnings growth.  <\/p>\n<p>  Chief executive Colin Goldschmidt on Tuesday said ongoing  headwinds from the strong Australian dollar had softened the  company&#039;s results but did not affect underlying performance.  <\/p>\n<p>    \"In a time of global uncertainty and weak economic conditions,    Sonic&#039;s operations continue to perform strongly, taking market    share from competitors and increasing margins through synergy    capture, tight cost control and revenue growth,&#039;&#039; Mr    Goldschmidt said in a statement.  <\/p>\n<p>    Sonic&#039;s Australian Pathology operations have continued the    turnaround which began in the second half of the 2011 financial    year.  <\/p>\n<p>    Mr Goldschmidt said the company recorded revenue growth of    eight per cent and more than 150 basis points of margin    improvement.  <\/p>\n<p>    The company said it was pleased with the outcome in a market    still challenged by high collection costs as a result of    changes to the regulations around collection centres.  <\/p>\n<p>    \"Our focus on quality, customer service and brand strength have    enabled us to grow market share despite opening proportionately    fewer collection centres than others,&#039;&#039; he said.  <\/p>\n<p>    Sonic&#039;s pathology operations in Germany were a standout    performer and the company&#039;s other European pathology    operations, including the radiology division and IPN, had also    performed strongly during the half year.  <\/p>\n<p>    The company&#039;s businesses in Belgium, Switzerland, the UK and    Ireland were tracking well.  <\/p>\n<p>    However, all US laboratory companies had been affected by the    weak US economy, causing low to flat organic revenue growth,    Sonic said.   <\/p>\n<\/p>\n<p>See the original post:<br \/>\n<a target=\"_blank\" href=\"http:\/\/www.adelaidenow.com.au\/business\/sonic-healthcare-grabs-market-share\/story-e6fredj3-1226276873102?from=public_rss\" title=\"Sonic Healthcare grabs market share\">Sonic Healthcare grabs market share<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> SONIC Healthcare lifted first half profit by eight per cent to $146 million as it continues to take a greater share of the market despite global uncertainty. &nbsp;The pathology and radiology provider said its net profit after tax was $146 million in the six months to December 31, 2011, up eight per cent from $143 million in the prior corresponding period.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/pathology\/sonic-healthcare-grabs-market-share.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[577487],"tags":[],"class_list":["post-245862","post","type-post","status-publish","format-standard","hentry","category-pathology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/245862"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=245862"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/245862\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=245862"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=245862"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=245862"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}